Minerva Neurosciences Inc To Discuss The Results Of Its Successful Phase 2b Clinical Trial Of Seltorexant MIN-202 In Insomnia Transcript
Good morning, everyone. Welcome to the June 24, 2019, Minerva Neurosciences conference call announcing the top line results from the company's Phase IIb trial in insomnia with seltorexant, a specific orexin-2 receptor antagonist.
A press release was issued this morning announcing data from this trial and providing conference call dial-in information.
Dr. Rémy Luthringer, Executive Chairman and Chief Executive Officer of Minerva, will be joined on the call today by 2 key opinion leaders in insomnia. Dr. Thomas Roth is Director of the Sleep Disorders and Research Center at the Henry Ford Hospital in Detroit, Michigan. Dr. David Kupfer is distinguished professor emeritus, department of psychiatry, University of Pittsburgh School of Medicine and a Board member of Minerva Neurosciences.
Dr. Luthringer will begin with brief introductory remarks. He will be followed by Dr. Roth and then by Dr. Kupfer. Dr. Luthringer will then provide a recap and open the floor to questions.
With that, I
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |